AgomAb Therapeutics NV (AGMB) News
Track canonical SquawkNews coverage tagged to AGMB, AgomAb Therapeutics NV. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AGMB Aligns With FDA
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
EARNINGS | Jun 23, 2026, 08:10 PM UTC
M
AGMB Designs NOV-ERA Study
Agomab announces design of NOV-ERA Phase 2b study with Ontunisertib in Fibrostenosing Crohn's Disease
EQUITY | Jun 23, 2026, 08:05 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
CRDO: Credo Initiated
Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis
EQUITY | Jun 22, 2026, 12:39 PM UTC
M
AGMB: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on AgomAb Therapeutics with a buy rating and a price target of $35
EQUITY | Jun 22, 2026, 11:05 AM UTC